This study examines the influences of liver enzymes on the overall survival in a number of patients with intrahepatic cholangiocarcinoma (ICC).
Aspirin's anti-inflammatory action is protective against another aggressive cancer: cholangiocarcinoma. Furthermore, it is beneficial regardless of daily use or dose.
New data from two clinical trials presented at the International Liver Congress 2013 demonstrated substantial improvements in the detection of both HCC and cholangiocarcinoma using diagnostic urine tests.
- Clinical Trials May Benefit Oncology Patients
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Rates of Infection with Clostridium Difficile Increase Over Time in Patients With Cancer
- Metabolism of Next-Generation Prostate Cancer Drugs Share Similarities
- Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|